Cover Image
市場調查報告書

EpiCast Report:高雪氏症 - 至2024年的流行病學預測

EpiCast Report: Gaucher Disease - Epidemiology Forecast to 2024

出版商 GlobalData 商品編碼 346489
出版日期 內容資訊 英文 42 Pages
訂單完成後即時交付
價格
Back to Top
EpiCast Report:高雪氏症 - 至2024年的流行病學預測 EpiCast Report: Gaucher Disease - Epidemiology Forecast to 2024
出版日期: 2015年11月06日 內容資訊: 英文 42 Pages
簡介

全球主要7個國家 (美國、法國、德國、義大利、西班牙、英國,以色列),確診為高雪氏症的患者數,預計I型從2014年的12,036人增加到2024年的13,006人,II型從2014年的121人到2024年的125人,III型從2014年的613人到2024年的640人。

本報告提供全球主要7個國家的高雪氏症調查分析、疾病的背景、危險因素和共生病症、全球趨勢、流行病學預測等相關的系統性資訊。

第1章 目錄

第2章 簡介

第3章 流行病學

  • 疾病的背景
  • 危險因素和共生病症
  • 全球趨勢
    • 美國
    • EU5個國家
    • 以色列
  • 預測手法
    • 利用之資訊來源
    • 未利用之資訊來源
    • 預測的前提條件與手法
  • 高雪氏症的流行病學預測
    • I型和確診的患者數
    • I型和確診的患者數 (各年齡)
    • I型和確診的患者數 (性別)
    • I型和確診的患者數 (年齡標準化) 等
  • 議論
    • 流行病學預測相關考察
    • 分析的限制
    • 分析的優勢

第4章 附錄

圖表

目錄
Product Code: GDHCER103-15

Gaucher Disease (GD) is a rare, inherited lysosomal storage disorder (LSD) that is classified into three forms - Types 1, 2, and 3 - which are distinguished by their symptoms, severity, and neurological involvement. GD affects the ability of cells to break down a specific type of fat, glucocerebroside (GC), as a result of the deficiency or limited activity of the enzyme glucocerebrosidase (GCase). This leads to the harmful accumulation of GC, which is also known as glucosylceramide, in the lysosomes, most commonly in the macrophages and monocytes, throughout the body. The most significant difference between the three types of GD is whether or not there is neurological involvement.

GlobalData epidemiologists forecast that the total prevalent cases of Type 1 GD in the 7MM will increase from 12,036 cases in 2014 to 13,006 cases in 2024, with the majority of cases occurring in the US and Israel. Types 2 and 3 GD are even more rare than Type 1, with only 121 cases of Type 2 and 613 cases of Type 3 across the 7MM in 2014. GlobalData epidemiologists predict that the total prevalent cases of Type 2 GD in the 7MM will increase from 121 cases in 2014 to 125 cases in 2024, and that the total prevalent cases of Type 3 GD in the 7MM will increase from 613 cases in 2014 to 640 cases in 2024. The disease affects men and women in equal numbers across the 7MM.

GlobalData epidemiologists used the available data on GD to the best extent possible to provide the most insightful epidemiological forecast for the total prevalent cases and type-specific cases of the disease in the 7MM. GlobalData epidemiologists conducted an exhaustive literature review, and used the most appropriate prevalence estimates. For Israel, where there is a high concentration of Ashkenazi Jews, GlobalData epidemiologists segmented the population into the general population and the Ashkenazi Jewish population, and used population-specific prevalence estimates for the forecast. This provides a more accurate estimate of the prevalence of GD in Israel, considering the higher disease prevalence among the Ashkenazi Jews as compared with the general population. For this forecast, GlobalData epidemiologists used a total GD prevalence estimate, which provides a truer picture of the disease burden within the 7MM.

Scope

  • The Gaucher Disease (GD) EpiCast Report provides an overview of the risk factors and global trends of GD in the 7MM (US, France, Germany, Italy, Spain, UK, and Israel). It includes a 10-year epidemiology forecast for the total prevalent cases of Type 1, 2, and 3 GD, segmented by age and sex in these markets.
  • The GD epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The GD EpiCast report will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global GD market.
  • Quantify patient populations in the global GD market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for GD therapeutics in each of the markets covered.
  • Identify the percentage of GD prevalent cases by disease type.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Reports

3. Epidemiology

  • 3.1. Disease Background
  • 3.2. Risk Factors and Comorbidities
  • 3.3. Global Trends
    • 3.3.1. US
    • 3.3.2. 5EU
    • 3.3.3. Israel
  • 3.4. Forecast Methodology
    • 3.4.1. Sources Used
    • 3.4.2. Sources Not Used
    • 3.4.3. Forecast Assumptions and Methods
  • 3.5. Epidemiological Forecast for Gaucher Disease (2014-2024)
    • 3.5.1. Total Prevalent Cases of Type 1 Gaucher Disease
    • 3.5.2. Age-Specific Total Prevalent Cases of Type 1 Gaucher Disease
    • 3.5.3. Sex-Specific Total Prevalent Cases of Type 1 Gaucher Disease
    • 3.5.4. Age-Standardized Total Prevalence of Type 1 Gaucher Disease
    • 3.5.5. Total Prevalent Cases of Type 2 Gaucher Disease
    • 3.5.6. Sex-Specific Total Prevalent Cases of Type 2 Gaucher Disease
    • 3.5.7. Total Prevalent Cases of Type 3 Gaucher Disease
    • 3.5.8. Age-Specific Total Prevalent Cases of Type 3 Gaucher Disease
    • 3.5.9. Sex-Specific Total Prevalent Cases of Type 3 Gaucher Disease
    • 3.5.10. Age-Standardized Total Prevalence of Type 3 Gaucher Disease
  • 3.6. Discussion
    • 3.6.1. Epidemiological Forecast Insight
    • 3.6.2. Limitations of the Analysis
    • 3.6.3. Strengths of the Analysis

4. Appendix

  • 4.1. Bibliography
  • 4.2. About the Authors
    • 4.2.1. Epidemiologists
    • 4.2.2. Reviewers
    • 4.2.3. Global Director of Therapy Analysis and Epidemiology
    • 4.2.4. Global Head of Healthcare
  • 4.3. About GlobalData
  • 4.4. About EpiCast
  • 4.5. Disclaimer

List of Tables

  • Table 1: 7MM, Sources Used to Forecast the Total Prevalent Cases of Gaucher Disease
  • Table 2: 7MM, Total Prevalent Cases of Type 1 Gaucher Disease, All Ages, Both Sexes, N, 2014-2024
  • Table 3: 7MM, Total Prevalent Cases of Type 1 Gaucher Disease, by Age, Both Sexes, N (Row %), 2014
  • Table 4: 7MM, Total Prevalent Cases of Type 1 Gaucher Disease, All Ages, N (Row %), by Sex, 2014
  • Table 5: 7MM, Total Prevalent Cases of Type 2 Gaucher Disease, Age ≥4 Years, Both Sexes, N, 2014-2024
  • Table 6: 7MM, Total Prevalent Cases of Type 3 Gaucher Disease, Age <40 Years, Both Sexes, N, 2014-2024
  • Table 7: 7MM, Total Prevalent Cases of Type 3 Gaucher Disease, by Age, Both Sexes, N (Row %), 2014

List of Figures

  • Figure 1: 7MM, Total Prevalent Cases of Type 1 Gaucher Disease, All Ages, Both Sexes, N, 2014-2024
  • Figure 2: 7MM, Total Prevalent Cases of Type 1 Gaucher Disease, by Age, Both Sexes, N
  • Figure 3: 7MM, Total Prevalent Cases of Type 1 Gaucher Disease, All Ages, N, by Sex, 2014
  • Figure 4: 7MM, Age-Standardized Total Prevalence of Type 1 Gaucher Disease (%), All Ages, by Sex, 2014
  • Figure 5: 7MM, Total Prevalent Cases of Type 2 Gaucher Disease, Age ≥4 Years, Both Sexes, N, 2014-2024
  • Figure 6: 7MM, Total Prevalent Cases of Type 2 Gaucher Disease, All Ages, by Sex, N, 2014
  • Figure 7: 7MM, Total Prevalent Cases of Type 3 Gaucher Disease, Age <40 Years, Both Sexes, N, 2014-2024
  • Figure 8: 7MM, Total Prevalent Cases of Type 3 Gaucher Disease, by Age, Both Sexes, N, 2014
  • Figure 9: 7MM, Total Prevalent Cases of Type 3 Gaucher Disease, Age <40 Years, by Sex, N, 2014
  • Figure 10: 7MM, Age-Standardized Total Prevalence of Type 3 Gaucher Disease (%), Age <40 Years, by Sex, 2014
Back to Top